Long-arginine-3 IGF-1 analog. Reduced binding to IGFBPs prolongs free IGF-1 activity ~3× standard IGF-1.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Originally developed as a research tool. Bypasses normal IGFBP buffering, leading to higher free-IGF-1 exposure. Physique-community use is widespread; clinical use is essentially nonexistent. Hypoglycemia and tissue-overgrowth concerns are real.
No human clinical use. Hypoglycemia risk is real. Long-term tissue-overgrowth and cancer-promotion concerns. Identity verification of grey-market product is poor.
Stack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
Mecasermin (recombinant IGF-1) is FDA-approved as Increlex for severe primary IGF-1 deficiency in pediatric growth disorders. IGF-1 LR3 is a long-acting analog used in research and bodybuilding contexts; not separately FDA-approved. Clinical IGF-1 replacement data is solid for the narrow approved indication.
A-tier — "more substantial research around it. It is an actual proven downstream of growth hormone being higher, which we obviously know is very anabolic." Uses 40 mcg pre-workout. Argues IGF-1 LR3 should NOT be paired with GH — they target the same pathway.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 20-50 µg · daily, subcutaneous
Draw volume is below 5 units — hard to measure accurately on most syringes. Consider adding more BAC water to dilute, or moving to a smaller syringe.
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
Research-grey — no clinical use